Finding the perfect name is no easy task for a new company, particularly in the exotic world of biopharma monikers. Mylan and Pfizer’s Upjohn business, working to close their generics megamerger, believe they have one that strikes the right tone—even
read moreNASH frontrunner Intercept Pharma presented a secondary analysis of its Regenerate study that found that treatment with Ocaliva led to “early and consistent improvements” in a range of noninvasive tests. More: Can noninvasive tests advance NASH diagnostics? Intercept analysis suggests
read moreJust two days before Amarin faces a pivotal FDA advisory committee to expand its label for fish-oil derivative Vascepa, the FDA has some questions about the key trial’s placebo control—namely, whether it skewed the drug’s “landmark” cardiovascular outcomes results. More: Will mineral-oil
read moreAs the immunology market gets even more crowded, drugmakers are eyeing new indications to expand their reach. Now, Novartis’ Cosentyx and Eli Lilly’s IL-17A rival med Taltz have rolled out detailed data in non-radiographic axial spondyloarthritis. More: Novartis' Cosentyx, Eli
read moreLonza, which has been expanding its cell manufacturing operation but still faces challenges in other parts of its business, will have to face those with a new CEO. Marc Funk is leaving after less than a year in the top
read moreThe money will go towards a potential new therapy and project, seeking to discover new ways that may prevent brain cell death. More: Parkinsons UK granted £200,000 for Virtual Biotech Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals